|

EGFR Inhibitor ERAS-801 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ERAS 801, ERAS-801, ERAS801

Pipeline

Phase 1: 1

Top Sponsors

  • Jonsson Comprehensive Cancer Center1

Indications

  • Resectable Astrocytoma1
  • IDH Wildtype Recurrent Glioblastoma1
  • Recurrent Astrocytoma1
  • IDH Wildtype Glioblastoma1
  • Resectable Glioblastoma1

Los Angeles, California1 trial

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

UCLA / Jonsson Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.